First order?Save 20%
(888) 510-7196
Shop
Learn
Lab Testing
SunshineGPT
10-Second Reorder
Free shipping!Every order through 9/30/26Free shipping on all orders
Go back
Caring SunshineIngredients

Endo-peptidase

Table of contents

Other Names

endopeptidaseendoproteaseendoproteinasepeptidasepeptide hydrolaseproteaseproteinaseproteolytic enzyme

Synopsis

Endopeptidase: A Comprehensive Reference on Naturally Derived Proteolytic Enzyme Supplements

1. Identity and Classification

Biochemical Definition

Endopeptidases are peptidases that break peptide bonds within a protein substrate, in contrast to exopeptidases, which break peptide bonds from one or both termini of the protein substrate. In the context of dietary supplementation, the term "endopeptidase" does not refer to a single compound but to a broad functional class of proteolytic enzymes, each with distinct natural origins, chemical identities, and mechanisms. Exopeptidases degrade terminal amino acid positions attached to polypeptide chains, while endopeptidases catalyze the breakdown of peptide bonds in the middle portion of polypeptide chains.

Endopeptidases employ various catalytic mechanisms; within this group are the aspartic endopeptidases, cysteine endopeptidases, glutamic endopeptidases, metalloendopeptidases, serine endopeptidases, and threonine endopeptidases. This classification reflects fundamental differences in the amino acids that form the active site of each enzyme subtype, as well as differences in pH optima, substrate specificity, inhibitor sensitivity, and biological origin.

Subclasses by Catalytic Mechanism

  • Serine endopeptidases: The serine endopeptidases represent one of the most abundant and diverse groups, with their apparently successful proteolytic mechanism having arisen independently many times throughout evolution, giving rise to the well-studied soluble chemotrypsins and subtilisins, among many others. The chymotrypsin family includes the mammalian enzymes such as chymotrypsin, trypsin, or elastase or kallikrein, and the subtilisin family includes the bacterial enzymes such as subtilisin. Prolyl endopeptidase (PEP) is a serine protease that recognizes and cleaves small peptides at internal proline residues.
  • Cysteine endopeptidases: Include bromelain (from pineapple) and papain (from papaya), which rely on a catalytic cysteine residue in their active site.
  • Metalloendopeptidases: Include serratiopeptidase (a zinc metalloprotease) and neprilysin (also a zinc metallopeptidase). The zinc-metalloprotease neprilysin (NEP) is one of the most prominent amyloid-beta degrading enzymes.
  • Aspartic endopeptidases: Endopeptidases are a group of hydrolases which catalyze the hydrolysis of peptidic bonds; these enzymes are also very chemo-, regio-, and enantioselective, which are active under soft reaction conditions (pH 6–8) and are easily handled biocatalysts.

Principal Naturally Derived Endopeptidases Used as Supplements

Several endopeptidases derived from plants, fungi, and microorganisms have been developed into dietary supplements. The most extensively researched are:

  • Bromelain — a cysteine endopeptidase complex from Ananas comosus (pineapple)
  • Papain — a cysteine endopeptidase complex from Carica papaya (papaya)
  • Serratiopeptidase (Serrapeptase) — a metalloendopeptidase from Serratia marcescens (originally isolated from the silkworm gut)
  • AN-PEP (Aspergillus niger prolyl endopeptidase) — a prolyl endopeptidase derived from the fungus Aspergillus niger
  • Neprilysin (NEP, neutral endopeptidase 24.11) — an endogenous mammalian metalloendopeptidase studied in the context of neurological health and aging

2. Natural Sources and Common Forms/Preparations

Bromelain (Ananas comosus)

Bromelain is a mixture of proteolytic enzymes primarily extracted from the fruit and stem of the pineapple plant (Ananas comosus). Bromelain is a complex combination of multiple endopeptidases of thiol and other compounds derived from the pineapple fruit, stem, and/or root. Fruit bromelain and stem bromelain are produced completely distinctly and comprise unique compounds of enzymes, and the descriptor "Bromelain" originally referred in actuality to stem bromelain. Stem bromelain is the predominant commercial form. Originally, bromelain was exclusively derived from Hawaiian pineapple stems, but it is now also manufactured in Taiwan, Thailand, Brazil, and Puerto Rico.

The enzyme complex includes thiol endopeptidases and several accessory compounds. It is composed of several endopeptidases and compounds like phosphatase, glucosidase, peroxidase, cellulase, escharase, and protease inhibitors. Bromelain is commercially available as oral tablets, capsules, and topical preparations. Pineapple products are available commercially in liquid, tablet, and capsule dose forms. Enzyme activity in commercial products is expressed in GDUs (gelatin digesting units) or MCUs (milk clotting units) per gram.

Papain (Carica papaya)

The papain food enzyme is a cysteine endopeptidase complex, containing papain (EC 3.4.22.2), chymopapain (EC 3.4.22.6), caricain (EC 3.4.22.30), and glycyl endopeptidase (EC 3.4.22.25), obtained from the latex of unripe Carica papaya L. The food enzyme papain (EC 3.4.22.2) is extracted from the latex of unripe Carica papaya L. Commercially it is available in tablets, capsules, and as a topical powder for wound debridement. Papain, a purified protein extracted from the latex of the unripe papaya, is widely used in traditional medicine.

Serratiopeptidase / Serrapeptase

Serrapeptase — also known as serratiopeptidase — is a proteolytic enzyme, meaning it breaks down proteins into smaller components called amino acids. It is produced by bacteria in the digestive tract of silkworms and allows the emerging moth to digest and dissolve its cocoon. Serratiopeptidase is a proteolytic enzyme prescribed in various specialties like surgery, orthopaedics, otorhinolaryngology, gynaecology, and dentistry for its anti-inflammatory, anti-edemic and analgesic effects. Modern commercial production uses fermentation of Serratia marcescens rather than silkworm extraction. The enzyme activity is measured in units. Serratiopeptidase 10 mg is equal to 20,000 units of enzyme activity.

AN-PEP (Aspergillus niger Prolyl Endopeptidase)

AN-PEP, a prolyl endopeptidase isolated from Aspergillus niger, is capable of degrading gluten and related peptides in the stomach itself before they reach the small intestine, as it is resistant to degradation by gastric juices in the stomach. Tolerase G, manufactured by DSM (Kaiseraugst, Switzerland), is a commercially available dietary supplement containing AN-PEP. It is sold in capsule and tablet form for use with meals.

Latiglutenase (ALV003)

Latiglutenase (formerly ALV003) is a combination of ALV001, an EP-B2 cysteine endopeptidase that is derived from the endosperm of germinating barley, and ALV002, a Sphingomonas capsulata prolyl endopeptidase (PEP). ALV001 degrades gluten proteins and reduces the immunogenic potential of gluten. This combination represents an investigational pharmaceutical/supplement product studied specifically in celiac disease.

Neprilysin (NEP)

Neprilysin (NEP) is a neutral endopeptidase, important for the degradation of amyloid beta (Aβ) peptides and other neuropeptides, including enkephalins, substance P, and bradykinin, in the brain, influencing various physiological processes such as blood pressure homeostasis, pain perception, and neuroinflammation. NEP is a type II integral membrane protein, known as zinc metallopeptidase, composed of 750 residues with an active site at its extracellular carboxyl-domain. Unlike the plant-derived endopeptidases, NEP is an endogenous human enzyme; research interest has focused on strategies to modulate or upregulate it rather than administer it exogenously as a supplement.

3. Traditional and Historical Use

Bromelain and Pineapple

The history of bromelain dates back to the ancient civilizations of South America, where the pineapple plant (Ananas comosus) is native. Indigenous peoples in Central and South America, particularly in regions like the Amazon rainforest and the Caribbean, used various parts of the pineapple plant for medicinal purposes, including treating digestive issues, reducing inflammation, and healing wounds. Historically, pineapple has been used in traditional and folk medicine to support digestion and reduce inflammation.

Bromelain was first isolated and described in the late 19th century by researchers in Europe, who identified its proteolytic properties. Since then, bromelain has gained recognition in both traditional and modern medicine for its potential therapeutic effects. The use of proteolytic enzymes like trypsin, chymotrypsin, and bromelain came into practice in the United States during the 1950s after it was observed that they had anti-inflammatory effects.

Papain and Papaya

Papain has been used in many countries such as England, Nigeria, Ghana, Gambia, India, and Jamaica. The latex of unripe papaya has a long ethnobotanical history as a digestive aid and wound-healing agent across Central America, Asia, and Africa. Unripe papaya was also historically used as a meat tenderizer, and papain's proteolytic properties were recognized empirically long before its enzyme chemistry was understood. Unripe papaya is also used as a vegetable in South and Southeast Asian cuisines.

Serratiopeptidase

The same observation of anti-inflammatory effects was made with serrapeptase in Japan during the late 1960s when researchers initially isolated the enzyme from the silkworm. Serratiopeptidase has since been used clinically in Japan, parts of Europe, and India as an anti-inflammatory agent across multiple medical specialties, including surgery, dentistry, and orthopedics. Unlike bromelain and papain, serratiopeptidase has no established pre-modern traditional use — its history is entirely pharmaceutical and dates from the latter half of the 20th century.

Prolyl Endopeptidases

The prolyl endopeptidase class has no documented traditional use as dietary supplements. A major area of research is the development of enzyme preparations able to digest the toxic fragments of gluten in the stomach, thus preventing exposure of these fragments to the intestinal mucosa. Endopeptidases produced by various plants, bacteria, or fungi have been studied and demonstrated to degrade, to different extents, the proline/glutamine-rich gluten peptides in the gastric and upper intestinal tracts, thus "detoxifying" gluten. These novel enzymes, termed "glutenases," could be devised as oral supplements, supporting the gluten-free diet and protecting from unintentional gluten exposures.

4. Key Constituents and Active Compounds

Bromelain Active Components

Bromelain is an effective chemoresponsive proteolytic enzyme derived from pineapple stems. It contains several thiol endopeptidases and is extracted and purified via several methods. The principal enzymatic components are stem bromelain (EC 3.4.22.32) and fruit bromelain (EC 3.4.22.33), which are cysteine proteases. Non-proteolytic components in the crude extract include peroxidases, acid phosphatases, and protease inhibitors, which may also contribute to the overall biological activity of the complex.

Papain Active Components

The papain complex contains four main cysteine endopeptidases: papain, chymopapain, caricain, and glycyl endopeptidase. Each enzyme has distinct but overlapping substrate specificities. Papain (EC 3.4.22.2) is the primary and best-characterized component, and the name "papain" is used conventionally to refer to the entire cysteine endopeptidase complex from papaya latex.

Serratiopeptidase Active Component

Serratiopeptidase is a single metalloprotease of the serralysin family, produced by Serratia marcescens. It requires zinc for catalytic activity and exhibits strong fibrinolytic, anti-edemic, and anti-inflammatory properties. Serratiopeptidase has been shown to decrease levels of IL-6 and TNF-α and promote fibrinolysis, aiding in edema resolution and faster healing.

AN-PEP Active Component

Prolyl endopeptidases (PEP, EC 3.4.21.24) hydrolyze internal proline residues in peptides. AN-PEP from Aspergillus niger is optimized for gastric conditions. AN-PEP is active between a pH of 2 and 8, with optimal activity between pH 4 and 5. It is not degraded by pepsin, thereby remaining fully functional in the stomach. It specifically degrades gluten epitopes by cleaving behind proline residues.

Neprilysin (NEP)

Prolyl endopeptidase (PEP) is a serine protease that recognizes and cleaves small peptides at internal proline residues. It is involved in the maturation and degradation of peptide hormones and neuropeptides. The mammalian enzyme neprilysin was first described in the cytosol of rabbit brain as an oligopeptidase which degrades the nonapeptide bradykinin at the Pro-Phe bond. The enzyme is involved in the maturation and degradation of peptide hormones and neuropeptides such as alpha-melanocyte-stimulating hormone, luteinizing hormone-releasing hormone (LH-RH), thyrotropin-releasing hormone, angiotensin, neurotensin, oxytocin, substance P, and vasopressin.

5. Established Mechanisms of Action

Proteolytic Digestion and Gastrointestinal Activity

Endopeptidases start the hydrolysis action from the peptide bond inside the protein. When consumed orally and retained in the gastrointestinal lumen, they can break down dietary proteins into smaller peptides and amino acids, facilitating digestion. However, a critical question for systemic effects is whether these enzymes survive gastric digestion and are absorbed intact.

Anti-Inflammatory Mechanisms (Bromelain)

The mechanism of action of bromelain appears to extend beyond its proteolytic activity as a digestive enzyme, encompassing a range of effects including mucolytic, anti-inflammatory, anticoagulant, and antiedematous effects. The pharmacological properties of bromelain are, in part, related to its arachidonate cascade modulation, inhibition of platelet aggregation, interference with malignant cell growth, anti-inflammatory action, and fibrinolytic activity. Evidence has shown that bromelain removes edema by fibrin degradation. In addition, bromelain inhibits the synthesis of pro-inflammatory prostaglandins, especially prostaglandin E2.

Anti-Inflammatory and Fibrinolytic Mechanisms (Serratiopeptidase)

Serratiopeptidase's applications are attributable to its versatile properties including anti-inflammatory, anti-biofilm, analgesic, anti-edemic, and fibrinolytic effects. The fibrinolytic action involves direct proteolytic degradation of fibrin deposits and bradykinin. Its ability to reduce viscosity of mucous secretions and penetrate biofilms has been investigated in respiratory and infectious disease contexts. It is also administered in conjunction with other antimicrobials, such as cephalexin, cefotiam, and sulbenicillin, to enhance their tissue penetration through its proteolytic properties.

Gluten Detoxification (AN-PEP and Prolyl Endopeptidases)

Gluten is characterized by a high abundance of glutamine and proline (15%). Proline residues are not accepted by most potential cleavage sites of proteases, which makes proline-rich gluten proteins resistant to digestion by enzymes of the human gastrointestinal tract. When these proteins reach the lamina propria of the small intestinal mucosa, they are modified by tissue transglutaminase, resulting in higher affinity for HLA-DQ2 and HLA-DQ8 molecules on antigen-presenting cells. In celiac disease, this leads to an abnormal immune reaction that can ultimately result in villous atrophy and malabsorption. AN-PEP counteracts this by cleaving the proline-containing immunogenic epitopes in the stomach before they reach the small intestine.

Amyloid-Beta Degradation (Neprilysin)

Neprilysin (NEP) is a neutral endopeptidase important for the degradation of amyloid beta (Aβ) peptides and other neuropeptides, including enkephalins, substance P, and bradykinin. NEP breaks down Aβ peptides into smaller fragments, preventing the development of detrimental aggregates such as Aβ plaques. NEP clears Aβ plaques predominantly by enzymatic breakdown in the extracellular space. Evidence is accumulating that the level of NEP declines with aging leading to decreased Aβ clearance. Since an accumulation of Aβ is considered to be a major factor in the etiology of Alzheimer's disease (AD), the decline in NEP with aging is likely a contributing factor to the progression of AD.

Prolyl Endopeptidase and Neuropeptide Regulation

Prolyl peptidases cleave proteins at proline residues and are of importance for cancer, neurological function, and type II diabetes. Prolyl endopeptidase (PEP) cleaves neuropeptides and is a drug target for neuropsychiatric diseases such as post-traumatic stress disorder, depression, and schizophrenia. The native enzyme exists in a conformationally flexible opened state with a large interdomain opening between the β-propeller and α/β-hydrolase domains; addition of substrate to preformed native crystals induces a conformational change consistent with an induced-fit rather than a simple lock-and-key catalytic mechanism.

6. Scientific Evidence by Area of Use

6.1 Gluten Digestion and Celiac Disease Support

AN-PEP: Clinical Evidence

Aspergillus niger prolyl endoprotease (AN-PEP) efficiently degrades gluten molecules into non-immunogenic peptides in vitro. Several human clinical trials have been conducted.

Study 1 (Salden et al., 2015 — Randomized Crossover in Healthy Volunteers): In a randomised, double-blind, placebo-controlled, cross-over study, 12 healthy volunteers attended four test days. A liquid low or high calorie meal (4 g gluten) with AN-PEP or placebo was administered into the stomach. AN-PEP efficiently degraded gluten in the stomach of the healthy subjects, irrespective of the caloric density of the meal and thus the gastric emptying rate.

Study 2 (Randomized Crossover in Gluten-Sensitive Subjects, 2017): This study investigated the efficacy of AN-PEP in a physiological meal setting. In a randomized placebo-controlled crossover study, 18 gluten-sensitive subjects consumed a porridge containing 0.5 g gluten together with two tablets either containing a high or low dose of AN-PEP, or placebo. Gastric and duodenal content was sampled over 180 minutes, and areas under the curve of gluten concentrations were calculated. The success rate of high dose AN-PEP, defined as at least 50% gluten degradation compared to placebo in the duodenum, was achieved in 10 of 13 comparisons. In the duodenum, gluten levels were reduced from 14.1 (8.3–124.7) in the placebo to 6.3 (3.5–19.8, p = 0.019) in the high dose and to 7.4 μg × min/ml in the low dose (3.8–12.0, p = 0.015). Thus even in a physiological meal setting, AN-PEP significantly degraded most gluten in the stomach before it entered the duodenum.

Study 3 (Randomized Placebo-Controlled Trial in Celiac Patients, 2024): This study examined the effects of orally administered Aspergillus niger prolyl endopeptidase protease (AN-PEP) on inadvertent gluten exposure and symptom prevention in adult celiac disease (CeD) patients following their usual gluten-free diet (GFD). This was an exploratory, double-blind, randomized, placebo-controlled trial that enrolled CeD patients on a long-term GFD. The primary objective was to investigate the effects of AN-PEP at a dose of 650 mg per meal, three times a day (during breakfast, lunch, and dinner) for 4 consecutive weeks, on involuntary gluten exposure in patients following a long-term GFD. The AN-PEP treatment did not significantly reduce the overall GIP stool concentration. However, given the observation of a significantly lower prevalence of patients with severe symptoms in the AN-PEP arm, further clinical research is warranted.

Evidence strength: Moderate for gastric gluten degradation in non-celiac subjects (two well-designed crossover RCTs in small samples); preliminary and inconclusive for clinical benefit in celiac disease patients on a GFD (one exploratory RCT, 2024). AN-PEP is not a treatment for celiac disease and is not intended to treat or prevent coeliac disease.

Latiglutenase (ALV003)

ALV001 degrades gluten proteins and reduces the immunogenic potential of gluten. Similarly, ALV002 catalyzes the postproline hydrolysis of proteins and peptides, similarly reducing the immunogenic potential of gluten. All escalating dose levels of ALV003 (100, 300, 900, and 1800 mg) were well tolerated with no serious adverse events or allergic reactions in Phase I single escalating-dose clinical trials. Evidence for latiglutenase is still in early clinical stages; large Phase III confirmatory trials demonstrating clinically meaningful mucosal protection in celiac disease patients had not been completed as of the available literature.

6.2 Anti-Inflammatory Effects and Pain

Bromelain

Few well-controlled clinical trials have been published to support the wide range of therapeutic claims for bromelain. Evidence exists primarily for the use of bromelain in debridement of burns and as an anti-inflammatory agent. Clinical trials have employed a variety of preparations including bromelain in combination with trypsin/rutin (as Phlogenzym) compared with diclofenac or placebo. Outcomes are equivocal, with older trials suggesting anti-inflammatory and analgesic effects.

In dentistry, a crossover randomized clinical trial examining bromelain for postoperative pain control after periodontal surgery found that the individuals who had used diclofenac and bromelain had considerably lower mean pain scores than those using a placebo. Bromelain's effect on postoperative pain was comparable to that of diclofenac sodium. Wisdom tooth extraction appears to be a well-established indication for bromelain treatment.

Little is known about the clinical use of bromelain in pediatrics, as most of the available data come from in vitro and animal studies, as well as a few RCTs in adults. Only a limited number of well-controlled clinical studies are available for bromelain, and results are often mixed.

Evidence strength: Limited but positive for post-surgical swelling and pain in dental contexts. Evidence for osteoarthritis, respiratory, and systemic inflammatory conditions is preliminary, based on small or methodologically limited trials, frequently using bromelain in combination products rather than alone.

Serratiopeptidase

Various published studies have reflected the use of serratiopeptidase for its anti-inflammatory, anti-edemic and analgesic effects. Some anecdotal studies suggest it also possesses anti-atherosclerotic effects. There were 6 clinical studies supporting the anti-inflammatory effects of serratiopeptidase.

A 2013 systematic review (Bhagat et al., International Journal of Surgery) covering the existing evidence concluded: The evidence supporting the use of serratiopeptidase as an anti-inflammatory and analgesic agent is based on clinical studies which are of poor methodology. Only few RCTs, which are usually placebo-controlled, with a small sample size, are available. The dose and duration of treatment was not specified in some studies, and the outcome of the study was not clearly defined in a few. Data on the safety and tolerability of serratiopeptidase are lacking in these studies.

A randomized controlled clinical trial in 133 patients (mean age 23 years) undergoing surgical removal of impacted mandibular third molars found that serratiopeptidase significantly improved trismus compared with control on the 4th day (27.30 ± 7.3 mm vs. 32.06 ± 7.7 mm, respectively; P < 0.001). Swelling also improved markedly. Serratiopeptidase has been clinically used in controlling surgical and non-surgical inflammatory conditions.

There is a dire need of conducting well-designed clinical trial-based studies for a wider spectrum of conditions and to limit the use of serratiopeptidase until its benefits and/or contraindications are substantially proven.

Evidence strength: Weak to moderate. While several RCTs show statistically significant benefits for swelling and pain in surgical contexts (particularly oral surgery), the overall evidence base is characterized by small sample sizes, methodological limitations, and lack of standardized dosing across studies. Systematic review conclusions have been cautious.

6.3 Respiratory Health

Both bromelain (mucolytic) and serratiopeptidase (mucolytic and fibrinolytic) have been investigated in chronic airway disease. Bromelain has been reported as having positive effects on the respiratory, digestive, and circulatory systems, and potentially on the immune system. The improvements observed in one pilot study may be attributable to the fibrinolytic and inflammation-modulating effects of serrapeptase and nattokinase. A recent review details the available in vitro, in vivo and clinical evidence for the anti-inflammatory, analgesic, anti-edemic and fibrinolytic effects of serrapeptase. However, there is much anecdotal evidence that systemic enzyme supplementation decreases cough and breathlessness, but robust human clinical evidence remains limited.

Evidence strength: Preliminary to weak; mostly in vitro, animal, or small uncontrolled human studies for the respiratory applications of these endopeptidases. Well-powered RCTs are lacking.

6.4 Neurological Health and Amyloid-Beta Clearance (Neprilysin)

Direct degradation of Aβ by endopeptidases has emerged as one important pathway for clearance. Of particular interest are endopeptidases that are sensitive to the neprilysin (NEP) inhibitors thiorphan and phosphoramidon, as these inhibitors induce a dramatic increase in Aβ levels in rodents. NEP deficiency results in twofold elevated levels of endogenous Aβ40 and Aβ42 in different brain regions and in defects in the degradation of exogenously administered Aβ42.

Research on modulating NEP with natural compounds has been conducted largely at the cellular and animal levels. While natural compounds are often recognized for upregulating NEP activity, some also have the ability to downregulate this enzyme. Researchers have reported that 3,5,3′-triiodothyronine isolated from Bos taurus domesticus acts as an inhibitor of neutral endopeptidase (NEP) activity. Additionally, several flavonoids isolated from Epilobium angustifolium, such as oenothein B and quercetin-3-O-glucuronide, have been identified as effective direct inhibitors of NEP.

Various preclinical studies show promising results in the clearance of Aβ, suggesting gene transfer strategies may be useful in the development of alternative therapies for neurodegenerative diseases. Further studies suggested that NEP-based gene therapy can improve cognitive function and potentially slow down the progression of neurodegenerative diseases, mainly AD.

Evidence strength: Preclinical only (animal and in vitro). No human clinical trials of dietary endopeptidase supplementation targeting brain neprilysin activity are available in the literature reviewed. This is an area of active basic and translational research, not an established therapeutic application.

6.5 Digestive Health and Protein Digestion

The most biologically intuitive application of dietary endopeptidases is to supplement impaired digestion of dietary protein. The endopeptidase does not degrade proteins but degrades peptides, and thus can be used together with other proteolytic enzymes such as proteinases and aminopeptidases to effectively produce protein hydrolysate used for foods and drinks. Bromelain and papain are both widely used as meat tenderizers and digestive aids, but robust human clinical evidence for their efficacy as standalone digestive enzyme supplements in healthy populations is limited. Previous in vitro studies demonstrated that some glutenases are efficient in catalyzing the digestion of gluten proteins in acidic conditions, reporting degradation of up to 70–99% of gluten protein load.

6.6 Burn Wound Debridement (Bromelain/Papain)

Research supporting bromelain medical uses remains limited, although evidence is strongest for enzymatic burn debridement and certain inflammation-related conditions. Topical bromelain-derived products (notably NexoBrid® in the European Union) have received regulatory approval for enzymatic debridement of burns, representing the most robustly evidenced clinical application among all naturally derived endopeptidase products. This application differs from oral supplementation in that the enzyme is applied directly to tissue.

7. Body Systems and Health Areas Associated with Endopeptidase Supplements

  • Gastrointestinal system: Protein digestion support; gluten detoxification (AN-PEP, latiglutenase); general digestive enzyme support (bromelain, papain).
  • Musculoskeletal system: Anti-inflammatory and analgesic applications in osteoarthritis, sports injuries, and post-surgical recovery (bromelain, serratiopeptidase). Bromelain is a natural remedy for easing arthritis symptoms, including joint pain and stiffness.
  • Cardiovascular and circulatory system: Fibrinolytic effects, anticoagulant and antithrombotic properties. Bromelain has been shown to represent a crucial role as an antiedematous, fibrinolytic, anticancer, anti-inflammatory, antibiotic, anticoagulant, and antithrombotic agent.
  • Respiratory system: Mucolytic effects in chronic airway disease; reduction of mucus viscosity (bromelain, serratiopeptidase).
  • Immune system: Bromelain has been shown to exert significant anti-inflammatory activity and may modulate adipocyte metabolism, potentially alleviating comorbidities associated with excess adiposity.
  • Central nervous system: NEP's role in neuropeptide regulation and amyloid-beta clearance; prolyl endopeptidase (PEP) as a drug target in neuropsychiatric disease research. Prolyl endopeptidase (PEP) cleaves neuropeptides and is a drug target for neuropsychiatric diseases such as post-traumatic stress disorder, depression, and schizophrenia.
  • Integumentary system (topical applications): Wound debridement, burn eschar removal (topical bromelain and papain).

8. Dosage Forms and Dosages Reported in Studies

Bromelain

The usual dosage of bromelain is 40 mg taken 3 or 4 times daily. Pineapple products are available commercially in liquid, tablet, and capsule dose forms. Most products contain bromelain 500 mg; manufacturers suggest a dose of 500 to 1,000 mg daily. Bromelain activity is often measured in GDUs or MCUs; standardization varies between products and countries. Clinical trials have used a wide range of doses and formulations, making direct comparison difficult.

Serratiopeptidase

The enzyme activity is measured in units. Serratiopeptidase 10 mg is equal to 20,000 units of enzyme activity. Clinical studies have typically used doses ranging from 5 mg to 30 mg (10,000–60,000 units) per day in divided doses. The randomized clinical trial examining third molar surgery used serratiopeptidase for 5 days, as described in the study protocol.

AN-PEP

AN-PEP was studied at a dose of 650 mg per meal, three times a day (during breakfast, lunch, and dinner) for 4 consecutive weeks in the 2024 celiac disease trial. Earlier healthy-volunteer studies used doses delivered intragastrically with 4 g of gluten per meal; the 2017 crossover trial used two tablets containing either a high or low dose of AN-PEP with a porridge containing 0.5 g gluten.

Latiglutenase (ALV003)

Escalating dose levels of ALV003 studied in Phase I trials were 100, 300, 900, and 1800 mg. All dose levels were well tolerated.

9. Safety Considerations and Known Interactions

Bromelain

Due to the efficacy of oral administration in the body, as a safe phytotherapeutic medication, bromelain was commonly suited for patients due to lack of compromise in its peptidase efficacy and the absence of undesired side effects at typical supplemental doses. However, cross-reaction with honeybee venom, olive tree pollen, celery, cypress pollen, and papain have been reported. Information regarding safety and efficacy in pregnancy and lactation is lacking. Dietary supplements such as bromelain are not approved by the U.S. Food and Drug Administration (FDA) to diagnose, treat, cure, or prevent disease. Bromelain's antiplatelet and fibrinolytic properties raise concerns for concurrent use with anticoagulant and antiplatelet medications.

Papain

EFSA safety evaluations have extensively assessed papain's endopeptidase complex. Among the four proteins in the cysteine endopeptidase complex, papain and chymopapain are known food allergens. Homology searches of the amino acid sequences of the four proteins in the complex to known allergens identified matches with six food and eight respiratory allergens. The Panel considered that a risk of allergic reactions upon dietary exposure to the food enzyme cannot be excluded. Based on the data provided, the origin of the food enzyme being an edible plant source and the estimated dietary exposure, the Panel concluded that the food enzyme does not give rise to safety concerns under the intended conditions of use.

Administration of chymopapain for chemonucleolysis resulted in sensitization in some patients. Severe systemic reactions mediated by papain-specific IgE were observed in some individuals that ingested papain-containing meat tenderizer. Cross-allergenicity with bromelain has been documented; caricain and glycyl endopeptidase showed 82.5%–87.5% sequence identity to papain and chymopapain, and IgE binding to caricain and glycyl endopeptidase has been reported.

Serratiopeptidase

There are no clinical studies reporting any drug interactions. The only available information is from drug company monographs. If administered along with warfarin, clopidogrel, or aspirin, as well as with other natural remedies such as garlic, fish oil, and turmeric, there may be increased risk of bleeding or bruising. A case of serrapeptase-induced lung injury manifesting as acute eosinophilic pneumonia has been reported in the literature, representing a rare but serious adverse event.

AN-PEP

AN-PEP is resistant to degradation by gastric juices in the stomach. The clinical trials reviewed reported no significant safety signals; however, the study populations have been small and follow-up periods short. Individuals with known Aspergillus allergies should exercise caution. The 2024 celiac disease RCT reported no significant harms attributable to AN-PEP in its patient population.

General Cross-Class Considerations

As a class, orally administered endopeptidases present several consistent safety considerations: (1) potential for allergic sensitization, particularly in atopic individuals or those with latex-fruit allergy syndrome; (2) potentiation of anticoagulant and antiplatelet drug effects due to fibrinolytic activity; (3) theoretical enhancement of absorption of co-administered drugs via increased intestinal permeability; bromelain has been shown to improve recovery after tissue damage and boost drug absorption, particularly for antibiotics. Data on the safety and tolerability of serratiopeptidase are lacking in the available clinical studies, a limitation that applies broadly across the naturally derived endopeptidase supplement category. Robust long-term safety data from large, well-controlled human trials are not yet available for most of these enzymes in supplemental contexts.

References

Health Conditions

Health conditions that Endo-peptidase may help support.

  • No conditions available.

Body Systems

Body systems that Endo-peptidase may help support.

  • No body systems available.
Join our newsletter

Stay informed. Stay healthy.

Get expert supplement tips, exclusive discounts, and product recommendations delivered to your inbox